GM1在新生儿缺氧缺血性脑病中的作用及疗效观察  

The role and curative effect of monostalotetrahexosylgangliside 1 on infants with neonatal hypoxic-ischemic encephalopathy

作　　者：张慧琼[1] 谭建新[1] 陈日玲[1] 

机构地区：[1]广东医学院附属医院儿科,广东湛江524001

出　　处：《中国妇幼保健》2009年第13期1796-1798,共3页Maternal and Child Health Care of China

摘　　要：目的:探讨GM1治疗新生儿缺氧缺血性脑病的疗效及其可能机制。方法:72例新生儿缺氧缺血性脑病患儿,随机分为GM1治疗组40例和常规治疗组32例,并选取正常新生儿20例作为对照组。治疗组及对照组分别在生后24 h内及药物治疗7天后抽血检测血浆MDA及SOD浓度,并对GM1治疗组及常规治疗组在生后1～3天、4～6天、7～10天进行NBNA评分。结果:①GM1治疗组其临床症状和体征改善明显优于常规治疗组(P<0.01)。②GM1治疗组生后4～6天、7～10天NBNA评分明显高于常规治疗组(P<0.05)。③GM1治疗组其血浆MDA水平较常规治疗组明显下降,而SOD水平明显升高(P<0.01)。结论:GM1通过降低脂质过氧化反应,增强抗氧化酶活性,促进新生儿缺氧缺血性脑病患儿病情恢复,发挥神经保护作用。Objective： To explore the mechanisms and curative effect of monostalotetrahexosylgangliside 1 （GM1） on infants with neonatal.hypoxic- ischemic encephalopathy. Methods： 72 cases were divided into two group randomly, including 40 cases as GMI treatmerit group and 32 cases as routine treatment group. 20 healthy infants were collected as control group. The levels of blood plasma MDA and SOD were separately detected in treatment group and control group after birth and on seventh day after aeatment. The NBNA grade were measured in GMI treatment group and routine treatment group after 1 -3 days, 4 -6 days and 7 - 10 days. Results： ①Ameliorated extent of clinical symptoms and physical signs between GM 1 treatment group and routine treatment group had significant difference （P 〈 0. 01 ） . The NBNA grades aider 4 - 6 days and 7 - 10 days in GMI treatment group were higher than those in routine treatment group （ P 〈 0. 05） . ③The level of MDA in GM1 treatment group was lower than that in routine treatment group, the level of SOD reversed （P 〈0.01） . Conclusion： GMI can enhance the activity of anti -oxidation enzyme by reducing the lipid over -oxidation, promote the cure of neonatal hypoxic -isebemic encephalopathy and play an neuro protective role in the disease.

关 键 词：神经节苷脂 新生儿缺氧缺血性脑病 疗效 

分 类 号：R722.19[医药卫生—儿科]